ABL Bio Inc. (KOSDAQ: 298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
32,500
-350 (-1.07%)
Jan 17, 2025, 9:00 AM KST
53.30%
Market Cap 1.57T
Revenue (ttm) 32.32B
Net Income (ttm) -49.04B
Shares Out 48.28M
EPS (ttm) -1,022.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 638,900
Average Volume 729,682
Open 32,850
Previous Close 32,850
Day's Range 31,750 - 33,050
52-Week Range 18,960 - 43,300
Beta 0.96
RSI 57.08
Earnings Date Mar 14, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.